An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer’s Disease

Registry ID

2026-525539-18-00

Source registry

CTIS

Status

Authorised

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

Merry Life Biomedical Co. Ltd.

Enrollment

70

Last update

2026-08-14

Conditions

• Early Alzheimer’s Disease
• Diseases [C] - Nervous System Diseases [C10]

Primary outcomes

1. Primary efficacy endpoint: Change in the Clinical Dementia Rating -Sum of Boxes (CDR-SB) from baseline to Week 52.

Locations

• , , Sweden

Related clinical trials

• A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma
• A Phase 1b/2 Study to Evaluate NB-4746 in Participants with Amyotrophic Lateral Sclerosis.
• EUROpean pragmatic multicenter randomized trial on platelet inhibition and/or lipid lowering treatment in Covert Brain Infarction (CBI)
• The efficacy and Safety of Intravenous thrombolysis in acute ischemic stroke patients with recent ingestion of Factor Xa-inhibitors Trial (SIFT)
• Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS)
• A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease

View on source registry